Bio Pharma Dive

NOVEMBER 9, 2020

The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact.

Antibody 330

Antibody Drugs 330

Bio Pharma Dive

APRIL 3, 2024

The startup claims to have a more efficient way to develop biologic drugs that treat disease by turning on cellular pathways, rather than blocking them.

Antibody 280

Antibody Drugs Development 280

Bio Pharma Dive

NOVEMBER 5, 2020

Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround.

Antibody 334

Antibody Drugs 334

Pharmaceutical Technology

OCTOBER 17, 2023

LegoChem Biosciences has entered an exclusive worldwide licensing agreement with Glycotope to develop an antibody-drug conjugate (ADC).

Antibody 130

Antibody Development Drugs Licensing 130

Pharmaceutical Technology

SEPTEMBER 28, 2023

Ono Pharmaceutical and Adimab have signed a drug discovery collaboration agreement for the development of antibody drugs in oncology

Antibody 130

Antibody Development Drugs 130

Bio Pharma Dive

APRIL 19, 2021

Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests.

Antibody 332

Antibody Drugs Development 332

BioSpace

APRIL 12, 2024

This week’s American Association for Cancer Research annual meeting drove home the importance of antibody-drug conjugates as an emerging class of potential anti-cancer therapeutics.

Antibody 125

Antibody Drugs Research 125

Bio Pharma Dive

JUNE 2, 2024

Study results showed the antibody-drug conjugate helped stave off disease progression better than a standard treatment. But eye-related side effects remained common.

Drugs 289

Drugs Antibody 289

Pharmaceutical Technology

AUGUST 24, 2023

Japan has granted a new drug substance patent for BioArctic’s monoclonal antibody (mAb), BAN0805, to treat Parkinson’s disease.

Antibody 245

Antibody Drugs 245

Bio Pharma Dive

JULY 28, 2021

The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech.

Antibody 288

Antibody Drugs Development 288

Bio Pharma Dive

SEPTEMBER 14, 2020

Merck's deal for Seattle Genetics' antibody-drug conjugate comes as Gilead agreed to acquire rival developer Immunomedics in the biotech industry's largest buyout of 2020.

Genetics 294

Genetics Antibody Drugs Development 294

Pharmaceutical Technology

MAY 28, 2024

J&J has made its second dermatology deal this month, adding Numab’s bispecific antibody NM26 to its growing atopic dermatitis drug portfolio.

Antibody 130

Antibody Dermatology Drugs 130

Bio Pharma Dive

JANUARY 12, 2021

Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction. BioNTech, meanwhile, could report critical new vaccine results in days.

Antibody 291

Antibody Vaccination Vaccine Drugs 291

Bio Pharma Dive

DECEMBER 8, 2020

But a growing group of antibody drugs, several of which were showcased at ASH, aren't far behind. Two cell therapies might soon be approved for the blood cancer.

Antibody 288

Antibody Drugs 288

Pharmaceutical Technology

AUGUST 29, 2022

Sanyou Biopharmaceuticals and Shanghai KangaBio have signed a licencing agreement to expedite the development and innovation of the former’s monoclonal antibody drug. The companies have earlier signed a partnership agreement for two monoclonal antibody drugs of Sanyou and also entered a high-level term sheet.

Antibody 130

Antibody Development Drugs Production 130

Pharmaceutical Technology

OCTOBER 21, 2022

AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

Antibody 217

Antibody Protein Licensing Licensing 217

Bio Pharma Dive

OCTOBER 14, 2020

Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19.

Antibody 248

Antibody FDA Approval Drugs Development 248

Bio Pharma Dive

FEBRUARY 5, 2024

The pharma disclosed positive results from two studies testing its antibody drug nipocalimab in generalized myasthenia gravis or Sjögren's disease.

Drugs 305

Drugs Antibody 305

Pharmaceutical Technology

NOVEMBER 24, 2023

China’s NMPA has approved ArkBio IND application for its respiratory syncytial virus (RSV) neutralising antibody, AK0610.

Antibody 130

Antibody Drugs 130

Bio Pharma Dive

JUNE 29, 2023

The yet-to-be-announced deal for the German biotech is the latest move by Lilly to bulk up its oncology business, adding a drug in early development for solid tumors.

Antibody 224

Antibody Drugs Development 224

Pharmaceutical Technology

MARCH 9, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Monoclonal antibody drugs for cancer. Treatment with monoclonal antibodies also helps immune systems defend against cancer.

Antibody 130

Antibody Drugs DNA Vaccination 130

Pharmaceutical Technology

JULY 21, 2022

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.

Antibody 264

Antibody Compliance Licensing Licensing 264

Pharmaceutical Technology

DECEMBER 4, 2023

The $247m deal will focus on the use of generative artificial intelligence to develop an antibody therapy for an unnamed cancer.

Antibody 162

Antibody Drugs Development 162

Pharmaceutical Technology

FEBRUARY 22, 2024

The company’s monoclonal antibody therapy, IO-202, has received its second orphan drug designation as a treatment for a blood cancer, CMML.

Antibody 130

Antibody Drugs 130

Fierce Pharma

FEBRUARY 20, 2024

After laying out plans to absorb a pair of production subsidiaries in October, Japan’s Daiichi Sankyo is doubling down on its quest to dominate the red-hot antibody-drug conjugate (ADC) field. Aiming to beef up development and manufacturing of antibody-drug conjugates, Daiichi Sankyo is plugging roughly €1 billion ($1.08

Antibody 110

Antibody Production Drugs Manufacturing 110

Drug Discovery World

JUNE 24, 2024

This eBook explores the challenges and opportunities in the therapeutic antibody market, the range of applications for these therapies and the move towards more targeted and effective next-generation antibody treatments.

Antibody 52

Antibody Drugs Marketing 52

BioPharma Reporter

JULY 11, 2024

Amid a period of clinical holds and legal tangles, the US antibody specialist CytoDyn has reached a settlement to resolve legal disputes with its former contract research organization (CRO) Amarex Clinical Research.

Antibody 76

Antibody Drug Trials Clinical Research Trials 76

Drug Discovery World

JUNE 25, 2024

A new eBook, sponsored by Sino Biological, is now available for download entitled ‘ The impact of therapeutic antibody discovery ’. The first monoclonal antibody (mAb), Orthoclone, was approved in 1986 to help prevent rejection in organ transplantation.

Antibody 52

Antibody Clinical Research Drugs Research 52

Pharmaceutical Technology

FEBRUARY 14, 2023

Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for CRB-701.

Antibody 130

Antibody Drugs Clinical Development Licensing 130

Bio Pharma Dive

JUNE 18, 2021

drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca.

Antibody 343

Antibody Drugs 343

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). The post LegoChem, Amgen partner to develop antibody drug conjugates appeared first on Pharmaceutical Technology.

Antibody 130

Antibody Development Drugs Licensing 130

Bio Pharma Dive

APRIL 21, 2023

A decision by the Supreme Court could have far-reaching effects on the lucrative market for antibody drugs, spurring responses from many of the industry’s top companies.

Antibody 183

Antibody Marketing Drugs 183

Bio Pharma Dive

MAY 24, 2021

Pharma and biotech companies alike see potential in using bispecific antibodies for hard-to-treat cancers like leukemia, myeloma and solid tumors.

Antibody 305

Antibody Drugs 305

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. Financing When it comes to looking to the future in the drug discovery industry, an important question to ask is: Where is the money?

Antibody 98

Antibody Marketing Drugs Licensing 98

pharmaphorum

DECEMBER 19, 2023

Big pharma companies like Pfizer are making significant investments in antibody-drug conjugates, a promising class of therapies. This article explores the growing interest and recent developments, including FDA approvals and the potential impact on the pharmaceutical industry.

Antibody 97

Antibody FDA Approval Pharma Companies Drugs 97

Pharmaceutical Technology

JANUARY 9, 2023

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.

FDA Approval 246

FDA Approval Antibody Clinical Trials Clinical Trials 246

Bio Pharma Dive

NOVEMBER 5, 2020

The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection. Fast antibody testing, however, is spotty.

Antibody 294

Antibody Drugs 294